Greg Tsongalis Appointed to the AltheaDx Scientific Advisory Board

SAN DIEGO, CA--(Marketwire - May 08, 2009) -

AltheaDx, a world leader in the development of companion diagnostics and biopharma services, today announced the appointment of Dr. Greg Tsongalis to their Scientific Advisory Board. Dr. Tsongalis is the Director, Molecular Pathology, Acting Director, Clinical Chemistry, & Associate Professor, Dartmouth Medical School, Dartmouth-Hitchcock Medical Center & Norris Cotton Cancer Center.

“We are delighted to have Dr. Tsongalis join our Scientific Advisory Board,” said David Macdonald, CEO of AltheaDx. “Greg brings to our Board a depth of clinical experience in molecular pathology that will support the AltheaDx strategy of bringing theranostics into clinical use. I’m confident that Greg will provide valuable insight as we continue to advance our pipeline of projects and develop exciting new opportunities.”

AltheaDx provides its customers with a full range of molecular biopharma services; from biomarker discovery, clinical studies, diagnostic translation, through to reporting clinical results.

Dr. Tsongalis is certified as a high complexity clinical laboratory director and is currently the Director of Molecular Pathology, Acting Director of Clinical Chemistry, and co-director of the Pharmacogenomics program at the Dartmouth-Hitchcock Medical Center in Lebanon, NH. He received his Ph.D. in Pathology from the University of Medicine and Dentistry of New Jersey and completed his postdoctoral training in Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill. His area of expertise is in clinical molecular diagnostic applications for genetic, hematologic, infectious, and neoplastic diseases. His research interests are in the pathogenesis of solid tumors, disease association of SNP genotyping and personalized medicine. He has authored/edited five textbooks in the field of molecular pathology, published more than 100 peer reviewed manuscripts, and has been an invited speaker at both national and international meetings. Dr. Tsongalis has been the recipient of numerous investigator/scientist awards. He has served on numerous committees of the AACC, AMP and ASIP. He is on the editorial board of Archiv Pathol Lab Med J Clin Virol, and Exper Molec Pathol, as well as, numerous corporate scientific advisory boards.

About AltheaDx

AltheaDx is bringing theranostics into clinical use. The goal of AltheaDx is to reduce the time and risk of therapeutic development and to provide high-value testing services. For additional information, please visit: www.altheadx.com.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: biomarkers companion diagnostics personalized medicine gene expression prostate cancer